Development and Validation of Novel Signature to Predict Overall Survival in "Driver-Gene-Negative" Lung Adenocarcinoma (LUAD): Results of a Multicenter Study

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2545

Related search